Jeffrey Landau
Corporate Officer/Principal at CYTOMX THERAPEUTICS, INC.
Net worth: 200 158 $ as of 30/05/2024
Jeffrey Landau active positions
| Companies | Position | Start | End |
|---|---|---|---|
| CYTOMX THERAPEUTICS, INC. | Corporate Officer/Principal | 31/03/2021 | - |
Career history of Jeffrey Landau
Former positions of Jeffrey Landau
| Companies | Position | Start | End |
|---|---|---|---|
| CATALYST BIOSCIENCES | Corporate Officer/Principal | 17/04/2016 | 28/02/2021 |
Threshold Pharmaceuticals, Inc.
 Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Sales & Marketing | 31/12/2011 | - |
Training of Jeffrey Landau
| Virginia Polytechnic Institute & State University | Undergraduate Degree |
| Stanford Graduate School of Business | Masters Business Admin |
Statistics
International
| United States | 6 |
Operational
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
| Masters Business Admin | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| CYTOMX THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Catalyst Biosciences, Inc.
 Catalyst Biosciences, Inc. BiotechnologyHealth Technology Catalyst Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA. | Health Technology |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
- Stock Market
- Insiders
- Jeffrey Landau
- Experience